Aeterna Zentaris Inc
TSX:AEZS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Anhui Wantong Technology Co Ltd
SZSE:002331
|
CN |
|
N
|
Nelly Group AB (publ)
STO:NELLY
|
SE |
|
China Renaissance Holdings Ltd
HKEX:1911
|
CN |
|
Shenzhen Tongyi Industry Co Ltd
SZSE:300538
|
CN |
Aeterna Zentaris Inc
EPS (Diluted)
Aeterna Zentaris Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Aeterna Zentaris Inc
TSX:AEZS
|
EPS (Diluted)
-$14
|
CAGR 3-Years
-98%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$6
|
CAGR 3-Years
23%
|
CAGR 5-Years
132%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$14
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$15
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$41
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
22%
|
|
Aeterna Zentaris Inc
Glance View
Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The company is headquartered in Montreal, Quebec and currently employs 17 full-time employees. The firm's lead product, Macrilen (macimorelin), is an oral test indicated for the diagnosis of patients with adult growth hormone deficiency (AGHD). Macrilen (macimorelin) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor (GHSR-1a) and has uses in both endocrinology and oncology indications. The firm is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The company is also developing oral prophylactic bacterial vaccines against each of SARS-CoV-2, the virus that causes COVID-19, and Chlamydia Trachomatis. The firm focuses on the commercialization of macimorelin in Asia and the rest of the world.
See Also
What is Aeterna Zentaris Inc's EPS (Diluted)?
EPS (Diluted)
-14.9
USD
Based on the financial report for Mar 31, 2024, Aeterna Zentaris Inc's EPS (Diluted) amounts to -14.9 USD.
What is Aeterna Zentaris Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
8%
Over the last year, the EPS (Diluted) growth was -197%. The average annual EPS (Diluted) growth rates for Aeterna Zentaris Inc have been -98% over the past three years , 8% over the past five years .
